Antihypertensive, renal, inflammatory and oxidative stress effects of amlodipine and azelnidipine in patients with essential hypertensive

Trial Profile

Antihypertensive, renal, inflammatory and oxidative stress effects of amlodipine and azelnidipine in patients with essential hypertensive

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2012

At a glance

  • Drugs Amlodipine (Primary) ; Azelnidipine (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2012 New trial record
    • 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top